Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots

Reverse phase protein arrays (RPPA) measure the relative expression levels of a protein in many samples simultaneously. Observed signal from these arrays is a combination of true signal, additive background, and multiplicative spatial effects. Background subtraction alone is not sufficient to remove all nonbiological trends from the data. We developed a surface adjustment that uses information from positive control spots to correct for spatial trends on the array beyond additive background. This method uses a generalized additive model to estimate a smoothed surface from positive controls. When positive controls are printed in a dilution series, a nested surface adjustment performs an intensity-based correction. When applicable, surface adjustment is able to remove spatial trends and increase within slide replicate agreement better than background subtraction alone as demonstrated on two sets of arrays. This work demonstrates the importance of including positive control spots on the array.

[1]  William C Reinhold,et al.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. , 2003, Cancer research.

[2]  E. Petricoin,et al.  Signal pathway profiling of prostate cancer using reverse phase protein arrays , 2003, Proteomics.

[3]  Paul J Utz,et al.  Protein microarrays for multiplex analysis of signal transduction pathways , 2004, Nature Medicine.

[4]  Virginia Espina,et al.  Protein microarrays: Molecular profiling technologies for clinical specimens , 2003, Proteomics.

[5]  Emanuel F Petricoin,et al.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays , 2003, Proteomics.

[6]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[7]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[8]  Virginia Espina,et al.  Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma , 2005, Clinical Cancer Research.

[9]  Sw. Banerjee,et al.  Hierarchical Modeling and Analysis for Spatial Data , 2003 .

[10]  Emanuel F Petricoin,et al.  Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. , 2002, Briefings in functional genomics & proteomics.

[11]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[12]  Ioan Tabus,et al.  Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. , 2007, Journal of proteome research.

[13]  Christopher G. Chute,et al.  Cancer Informatics , 2002, Health Informatics.

[14]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[15]  Ioan Tabus,et al.  Dissection of Signaling Pathways in Fourteen Breast Cancer Cell Lines Using Reverse-Phase Protein Lysate Microarray , 2006, Technology in cancer research & treatment.

[16]  Stephen R Master,et al.  Diagnostic challenges for multiplexed protein microarrays. , 2006, Drug discovery today.

[17]  Zhenyu Ding,et al.  Predicting Cancer Drug Response by Proteomic Profiling , 2006, Clinical Cancer Research.

[18]  Gordon B Mills,et al.  Functional proteomic profiling of AML predicts response and survival. , 2009, Blood.

[19]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[20]  Emanuel F Petricoin,et al.  A systems biology approach to the pathogenesis of obesity‐related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis , 2007, Hepatology.

[21]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[22]  Alan Y. Chiang,et al.  Generalized Additive Models: An Introduction With R , 2007, Technometrics.

[23]  Ioan Tabus,et al.  Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays , 2006, Proteomics.

[24]  Heng Zhu,et al.  Protein microarrays. , 2006, BioTechniques.

[25]  Emanuel Petricoin,et al.  Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray , 2004, Laboratory Investigation.

[26]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[27]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Simon N. Wood,et al.  Generalized Additive Models , 2006, Annual Review of Statistics and Its Application.